INMED PHARMACEUTICALS INC. Depreciation Expense on Reclassified Assets
INMED PHARMACEUTICALS INC. (INM) reported Depreciation Expense on Reclassified Assets of $94.53 thousand for the 3-month period ending 2023-09-30, per its 10-Q filed 2023-11-14.
Discontinued › Expense Statement › Operating Expenses
us-gaap:DepreciationExpenseOnReclassifiedAssets · last filed 2023-11-14
- INMED PHARMACEUTICALS INC. depreciation expense on reclassified assets for the quarter ending 2023-09-30 was $94.53K, a 4.75% increase year-over-year.
- INMED PHARMACEUTICALS INC. depreciation expense on reclassified assets for the quarter ending 2023-03-31 was $91.94K, a 2.78% increase year-over-year.
- INMED PHARMACEUTICALS INC. depreciation expense on reclassified assets for the quarter ending 2022-12-31 was $90.39K, a 2.41% increase year-over-year.
- INMED PHARMACEUTICALS INC. depreciation expense on reclassified assets for the quarter ending 2022-09-30 was $90.24K, a 322.83% increase year-over-year.
| Period end | Depreciation Expense on Reclassified Assets 3 month | Depreciation Expense on Reclassified Assets 6 month | Depreciation Expense on Reclassified Assets 9 month |
|---|---|---|---|
| 2023-09-30 | $94.53K 10-Q · filed 2023-11-14 | ||
| 2023-03-31 | $91.94K 10-Q · filed 2023-05-15 | $182.32K derived: sum of 2 quarters · filed 2023-05-15 | $272.57K 10-Q · filed 2023-05-15 |
| 2022-12-31 | $90.39K 10-Q · filed 2023-02-17 | $180.63K 10-Q · filed 2023-02-17 | |
| 2022-09-30 | $90.24K 10-Q · filed 2023-11-14 | ||
| 2022-03-31 | $89.45K 10-Q · filed 2023-05-15 | $177.72K derived: sum of 2 quarters · filed 2023-05-15 | $199.06K 10-Q · filed 2023-05-15 |
| 2021-12-31 | $88.27K 10-Q · filed 2023-02-17 | $109.61K 10-Q · filed 2023-02-17 | |
| 2021-09-30 | $21.34K 10-Q · filed 2022-11-14 | ||
| 2021-03-31 | $22.33K 10-Q · filed 2022-05-13 | $44.16K derived: sum of 2 quarters · filed 2022-05-13 | $65.51K 10-Q · filed 2022-05-13 |
| 2020-12-31 | $21.83K 10-Q · filed 2022-02-14 | $43.18K 10-Q · filed 2022-02-14 | |
| 2020-09-30 | $21.35K 10-Q · filed 2021-11-10 | ||
| 2020-03-31 | $21.15K 10-Q · filed 2021-05-13 | $42.69K derived: sum of 2 quarters · filed 2021-05-13 | $49.92K 10-Q · filed 2021-05-13 |
| 2019-12-31 | $21.55K 10-Q · filed 2021-02-11 | $28.73K 10-Q · filed 2021-02-11 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Apimeds Pharmaceuticals US, Inc. (APUS) | United States | $0.008B | |
| Ensysce Biosciences, Inc. (ENSC) | United States | $0.008B | -0.37 |
| CNS Pharmaceuticals, Inc. (CNSP) | United States | $0.007B | |
| EXICURE, INC. (XCUR) | United States | $0.008B | -1.54 |
| Acurx Pharmaceuticals, Inc. (ACXP) | United States | $0.007B | -0.97 |
| SOLIGENIX, INC. (SNGX) | United States | $0.008B | |
| Imunon, Inc. (IMNN) | United States | $0.008B | -0.56 |
| SYNLOGIC, INC. (SYBX) | United States | $0.007B | |
| Bolt Biotherapeutics, Inc. (BOLT) | United States | $0.007B | -0.26 |
| Enveric Biosciences, Inc. (ENVB) | United States | $0.007B | -0.63 |